Recently, the U.S. Food and Drug Administration (FDA) approved the combination of dabrafenib and trametinib for the treatment of patients with BRAF V600E mutation-positive NSCLC [10]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.